Conversely, since inhibitors of respiratory Complex I can exert potent antitumor activity (Al Assi et al, 2024), hindering or reversing OXPHOS expansion through small-molecule destabilizers of native AIF-CHCHD4 complexes may provide opportunities for chemotherapeutics targeting tumor metabolic biochemistry and resistance (Das et al, 2024). This evidence concerns the gene CHCHD4 and neoplasm.